Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.

Benedetta Pellegrino, Daniela Boggiani, Chiara Tommasi, Dante Palli, Antonino Musolino

Abstract


Taxanes, including paclitaxel and docetaxel, are one of the most active cytotoxic agents in breast cancer  treatment  including  Her-2  positive  subtype characterized  by  aggressive  clinical  and pathological features since the early stage. However, their use is sometimes limited by the occurrence of hypersensivity reactions (HSRs) characterized by erythematous rashes, bronchospasm, respiratory distress, hypotension, and pulmonary edema. Cross-reactions between paclitaxel and docetaxel are described in literature with a rate ranging from 49% to 90%. Abraxane (nab-paclitaxel), an albumin-bound form of paclitaxel, has a different toxicity profile from solvent-based paclitaxel and a lower rate of HSRs. Interestingly, several authors have recently reported cases of patients who developed HSRs to taxanes, principally paclitaxel, and were then safety treated with Abraxane, suggesting the absence of cross-reactivity between these drugs. Based on these considerations, we report our clinical experience and perform a literature review on this topic with the aim to investigate the cross-reactivity between nab-paclitaxel and other taxanes, in particular with docetaxel. 


Keywords


hypersensivity reaction, breast cancer, nab-paclitaxel, neoadjuvant chemotherapy

Full Text: PDF

DOI: 10.23750/abm.v88i3.6138

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Article Metrics Graph

Metrics powered by OpenJournalSystems.com

ISSN: 2531-6745